HRMY Share Price Performance
US$33.99
0.92 (2.78%)
23.7% undervalued intrinsic discount
US$44.55
Fair Value
Price US$33.99
AnalystConsensusTarget US$44.55
AnalystHighTarget US$70.00
AnalystLowTarget US$31.00
Fair ValueUS$44.55
Share Pricen/a
Harmony Biosciences Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 153 Fair Values set on narratives written by author
HRMY Community Narratives
AN
Fair Value US$44.55 23.7% undervalued intrinsic discount
Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
1users have liked this narrative
0users have commented on this narrative
86users have followed this narrative
AN
Fair Value US$70 51.4% undervalued intrinsic discount
Aging Populations And WAKIX Trials Will Expand Rare Disease Treatment
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$31 9.6% overvalued intrinsic discount
WAKIX Reliance Will Invite Patent Expiry And Pricing Woes
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
Key Takeaways Expanding addressable markets and a diversified pipeline position Harmony for sustained revenue growth with reduced dependence on any single product. Strong commercial execution and strategic capital management enable continued R&D investment, life cycle extension, and resilience against future competition.Read more
1users have liked this narrative
0users have commented on this narrative
86users have followed this narrative
AN
US$44.55
23.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
15.77% p.a.
Profit Margin
26.96%
Future PE
9.9x
Share price in 2028
US$54.17
Aging Populations And WAKIX Trials Will Expand Rare Disease Treatment
Key Takeaways Robust WAKIX growth and expansion into new indications position Harmony for sustained, outsized revenue and margin gains beyond market expectations. Strong cash reserves and business development set up Harmony as a leading consolidator and innovator in rare neurological diseases and regenerative therapies.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$70
51.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
21.25% p.a.
Profit Margin
31.01%
Future PE
11.78x
Share price in 2028
US$85.12
WAKIX Reliance Will Invite Patent Expiry And Pricing Woes
Key Takeaways Over-reliance on a single key product exposes the company to concentration risk and vulnerability when patent protections expire or rivals enter the market. Evolving payer, regulatory, and scientific landscapes threaten pricing power, future earnings visibility, and long-term demand for the company's portfolio.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$31
9.6% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
13.24% p.a.
Profit Margin
23.44%
Future PE
8.47x
Share price in 2028
US$37.7
Snowflake Analysis
Harmony Biosciences Holdings, Inc. Key Details
About HRMY
- Founded
- 2017
- Employees
- 268
- CEO
- WebsiteView website
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
